Number of children with clinical adverse event: vertigo · Patients with idiopathic acute vestibular dysfunction (vestibular neuritis)
Corticosteroids showed no clear difference in vertigo compared with placebo (low certainty).
1 finding from 1 review
Dizziness Handicap Inventory score · Patients with idiopathic acute vestibular dysfunction (vestibular neuritis)
1 finding from 1 review
Caloric extent of recovery (improvement as a % in lateralisation of electronystagmography on caloric testing) · Patients with idiopathic acute vestibular dysfunction (vestibular neuritis)
2 findings from 1 review
Complete caloric recovery · Patients with idiopathic acute vestibular dysfunction (vestibular neuritis)
Corticosteroids may leads to higher complete caloric recovery compared with placebo (low certainty).
2 findings from 1 review
Adverse effects · Patients with idiopathic acute vestibular dysfunction (vestibular neuritis)
1 finding from 1 review
Change in hearing threshold determined by PTA Range 0 dB to 140 dB Negative values represent lowering and positive values represent raising of the hearing threshold. A lower hearing threshold represents hearing improvement. Â · sudden sensorineural hearing loss
Intratympanic corticosteroids showed no clear difference in change in hearing threshold determined by PTA Range 0 dB to 140 dB… compared with systemic corticosteroids (low certainty).
1 finding from 1 review
Proportion of patients whose hearing is improved · sudden sensorineural hearing loss
Intratympanic corticosteroids showed no clear difference in proportion of patients whose hearing is improved compared with systemic corticosteroids (moderate certainty).
1 finding from 1 review
Final hearing threshold determined by PTA (a lower value represents better hearing) · sudden sensorineural hearing loss
Intratympanic corticosteroids showed no clear difference in final hearing threshold determined by PTA (a lower value represents… compared with systemic corticosteroids (low certainty).
1 finding from 1 review
Adverse eventsb · sudden sensorineural hearing loss
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Tympanic membrane perforation · sudden sensorineural hearing loss
1 finding from 1 review
Vertigo/dizziness: timing not reported · sudden sensorineural hearing loss
Intratympanic corticosteroids may leads to higher vertigo/dizziness: timing not reportedd compared with systemic corticosteroids (low certainty).
1 finding from 1 review
Vertigo/dizziness: at the time of injection · sudden sensorineural hearing loss
1 finding from 1 review
Ear pain: timing not reported · sudden sensorineural hearing loss
Intratympanic corticosteroids probably leads to higher ear pain: timing not reportedf compared with systemic corticosteroids (moderate certainty).
1 finding from 1 review
Ear pain: at the time of injection · sudden sensorineural hearing loss
1 finding from 1 review
Disease severity as measured by patient‐reported symptom score (total nasal symptom score) · adults and children > 12 with non‐allergic rhinitis
1 finding from 1 review
Significant adverse event: epistaxis · adults and children > 12 with non‐allergic rhinitis
Intranasal corticosteroids probably leads to higher significant adverse event: epistaxis compared with placebo (moderate certainty).
1 finding from 1 review
Disease‐specific health‐related quality of life Short Form 12 (SF‐12v2) (range 0 to 800) · adults and children > 12 with non‐allergic rhinitis
1 finding from 1 review
Health outcomes Peak expiratory flow readings (higher readings indicate better peak flow) · adults and children > 12 with non‐allergic rhinitis
It is very uncertain whether intranasal corticosteroids changes objective measurement of airflow: peak flow rate (expiratory) compared with placebo (very low certainty).
1 finding from 1 review
Other adverse events · adults and children > 12 with non‐allergic rhinitis
Intranasal corticosteroids showed no clear difference in other adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Improvement in vertigo frequency · Ménière’s disease
Intratympanic corticosteroids showed no clear difference in improvement in vertigo frequency compared with placebo/no treatment (low certainty).
2 findings from 1 review